Table 1.

Baseline characteristics of HCC patients

Characteristic		Icaritin
	600 mg bid	800mg bid	Total
	(N = 14)	(N = 6)	(N = 20)
Median age, years (range)	61 (31–74)	43 (33–73)	58 (31–74)
Male, no.(%)	12 (85.7)	5 (83.3)	17 (85.0)
ECOG performance status, no.(%)
0	2 (14.3)	0 (0.0)	2 (10.0)
1	11 (78.6)	6 (100.0)	17 (85.0)
2	1 (7.1)	0 (0.0)	1 (5.0)
Macroscopic vascular invasion, no.(%)
Yes	5 (35.7)	2 (33.3)	7 (35.0)
No	9 (64.3)	4 (66.7)	13 (65.0)
Portal vein tumor thrombus, no.(%)
Yes	3 (21.4)	2 (33.3)	5 (25.0)
No	11 (78.6)	4 (66.7)	15 (75.0)
Bulky tumor*, no.(%)
Yes	1 (7.1)	1 (16.7)	2 (10.0)
No	13 (92.9)	5 (83.3)	18(90.0)
Extrahepatic metastasis, no.(%)
Yes	13 (92.9)	5 (83.3)	18 (90.0)
No	1 (7.1)	1 (16.7)	2 (10.0)
Extrahepatic metastatic site, no.(%)
Lymph node	7 (50.0)	4 (66.7)	11 (55.0)
Lung	7 (50.0)	3 (50.0)	10 (50.0)
BCLC stage, no.(%)
B	1 (7.1)	0 (0.0)	1 (5.0)
C	13 (92.9)	6 (100.0)	19 (95.0)
Number of tumor sites, no.(%)
1	2 (14.3)	1 (16.7)	3 (15.0)
2	6 (42.9)	1 (16.7)	7 (35.0)
3	3 (21.4)	2 (33.3)	5 (25.0)
≥ 4	3 (21.4)	2 (33.3)	5 (25.0)
Hepatitis virus status, no.(%)
HBV infection	12(85.7)	6 (100.0)	18 (90.0)
HCV infection	1 (7.1)	0 (0.0)	1 (5.0)
Liver cirrhosis, no.(%)
Yes	10 (71.4)	5 (83.3)	15 (75.0)
No	4 (28.6)	1 (16.7)	5 (25.0)
Child-Pugh classification, no.(%)
A	13 (92.9)	5 (83.3)	18 (90.0)
B	1 (7.1)	1 (16.7)	2 (10.0)
AFP > ULN (laboratory), no.(%)	13 (92.9)	6 (100.0)	19 (95.0)
Previous treatment, no.(%)
Surgery	3 (21.4)	4 (66.7)	7 (35.0)
TACE/RFA	11 (78.6)	3 (50.0)	14 (70.0)
Sorafenib or Chemo	1 (7.1)	3 (50.0)	4 (20.0)

*Bulky tumor: Tumor mass in liver ≥10cm. Abbreviations: ECOG: Eastern Cooperative Oncology Group; BCLC: Barcelona Clinic Liver Cancer; HBV: Hepatitis B Virus; HCV: Hepatitis C Virus; ULN: Upper Limits of Normal; TACE: Transarterial Chemoembolization; RFA: Radiofrequency Ablation